Long intergenic non-protein coding RNA 2285 (LINC02285)

Long intergenic non-protein coding RNA 2285 (LINC02285) is a long non-coding RNA gene locus not overlapping protein-coding genes, primarily identified as upregulated in ovarian cancer tissue and cell lines. High LINC02285 expression is linked to increased proliferation, migration, and resistance to copper-induced cell death, most notably with Elesclomol treatment. Experimentally, knockdown of LINC02285 suppresses ovarian cancer cell proliferation and migration, while overexpression enhances them. As such, LINC02285 is both a candidate therapeutic target and a prognostic biomarker for ovarian cancer, with its main biological impact mediated through the regulation of cuproptosis and possibly the PI3K-AKT pathway[2][4]. Broader review of lincRNA function highlights roles in chromatin remodeling, transcriptional regulation, and tissue-specific fine-tuning of gene expression, underscoring the potential of LINC02285 for clinical translation[3][5]. If further molecular or clinical evidence emerges, classification and disease roles could expand beyond ovarian cancer, but current data centers on its relevance in *cancer biology* and *cell death regulation*[2][4]. There are no approved drugs specifically targeting LINC02285 as of the latest research.

Other names

LINC02285

LINC02285 overexpression antagonizes Elesclomol-induced cuproptosis, promoting cell survival in ovarian cancer[2].